You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Selective Inhibitors of NaV as Therapeutics for Pain

    SBC: SITEONE THERAPEUTICS, INC.            Topic: 108

    PROJECT SUMMARY This program aims to develop a novel non opioid therapeutic for the treatment of pain that targets a subtype of the human voltage gated Na ion channel NaV Preliminary data indicate that SiteOneandapos s lead drug candidates may be more effective than opioids for treating certain types of pain and lack the side effects associated with opioid analgesics which include nausea ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Nanoparticle Delivery System for Ewing Sarcoma Treatment

    SBC: NANOVALENT PHARMACEUTICALS INC            Topic: 102

    DESCRIPTION provided by applicant This Phase I STTR project seeks to demonstrate proof of principle that novel targetable nanoparticles can delivery therapeutic substances to human tumor cells and reduce tumor burden in metastatic cancer The concept for these nanoparticles is based on the polymerized liposome nanoparticle PLN that displays functional antibodies that target tumor cell surfac ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Targeted Polymerized Shell Microbubbles to Image Surgical Adhesions

    SBC: NANOVALENT PHARMACEUTICALS INC            Topic: NIGMS

    DESCRIPTION provided by applicant The long term goal of this Phase I STTR project is to develop a commercially viable ultrasound contrast reagent UCR that will allow the noninvasive identification of newly forming abdominal adhesions after surgery Successful implementation would have significant impact because we would remove the impediment to clinical testing of anti adhesion therapies and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of an Open Speech Signal Processing Platform

    SBC: SensorLogic, Inc.            Topic: NIDCD

    This proposal will create an open speech signal processing platform The open computational framework will be used for developing algorithms that will help accelerate acoustic and hearing science research It will permit researchers to more rapidly and easily test new algorithms with greater control performance and ease Several example systems will be created to show that the platform can be ad ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis

    SBC: DERMAXON LLC            Topic: NIAMS

    Project Summary Abstract DermaXon s project goal is to develop efficacious novel selective inhibitors of CYP A for the topical treatment of ichthyosis Congenital ichthyosis is a family of hereditary disorders of keratinization characterized by dry scaling skin that may be thickened or very thin impacting the quality of life of patients and their family members Currently there is no cure f ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Novel antibacterial agents derived from natural products

    SBC: Promiliad Biopharma Incorporated            Topic: NIAID

    DESCRIPTION provided by applicant Antibiotic resistance among common bacterial pathogens is a serious public health problem as it compromises our ability to treat infectious disease The resistance problem is compounded by the lack of discovery of new antibiotics especially those with novel mechanisms of action New antibiotics are critically needed as resistance to recently developed antibiot ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Artificial Accessory Cell Bioreactor

    SBC: RESODYN CORPORATION            Topic: NHLBI

    DESCRIPTION provided by applicant This Small Business Innovation Research Phase I project will develop and demonstrate a commercially feasible Artificial Accessory Cell Bioreactor AACB that can be used for translational research applications and scale up of stem cell cultures to support the development of emerging cell therapy applications The proposed bioreactor has two unique aspects The ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government